Following publication of KEYNOTE-689 Phase 3 results confirming the role of perioperative checkpoint inhibition in head and neck cancer, GeoVax announced plans for a Phase 2 trial (AdPNP-203) ...
Q3 2025 product sales of $22.5 million, representing 129% growth over Q3 2024 and 19th straight quarter of sequential product sales growthQ3 2025 basic and fully diluted GAAP EPS of $(0.07), non-GAAP ...
THIRD QUARTER FINANCIAL RESULTS VANCOUVER, BC, Nov. 6, 2025 /PRNewswire/ - "Our portfolio of high-quality assets continued to deliver strong results, generating ...
Bragg Gaming Group ("Bragg" or the "Company"), a leading content and technology provider to the online gaming industry, today announced its financial results for the third quarter of 2025. Third ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback